17alpha-monoesters of cortexolone for use in the treatment of tumors

Abstract

The present invention provides certain cortexolone derivatives, and the same for use as antitumor active ingredients for the curative or adjuvant, or neoadjuvant or palliative treatment of precancerous lesions, dysplasias, metaplasias and tumor diseases, including malignant neoplasias and metastasis. The present invention also provides pharmaceutical compositions comprising the cortexolone derivatives as active ingredients and at least one physiologically acceptable excipient, and to the use of said pharmaceutical compositions as antitumor medicinal products.

What is claimed is: 
     
         1 . A pharmaceutical composition comprising a compound having formula: 
       
         
           
           
               
               
           
         
         and at least one physiologically acceptable excipient. 
       
     
     
         2 . The pharmaceutical composition of  claim 1 , comprising at least one other active ingredient. 
     
     
         3 . The pharmaceutical composition of  claim 2 , wherein the other active ingredient is a chemotherapeutic active ingredient. 
     
     
         4 . A method of treating a disease or disorder mediated by glucocorticoid, in a subject in need thereof, the method comprising administrating a therapeutically effective amount of a compound having formula: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutical composition comprising said compound and at least one physiologically acceptable excipient, to said subject. 
     
     
         5 . A method of treating a disease or disorder in a subject in need thereof, comprising administrating a therapeutically effective amount of compound having formula: 
       
         
           
           
               
               
           
         
         or a pharmaceutical composition comprising said compound and at least one physiologically acceptable excipient, to said subject. 
       
     
     
         6 . The method of  claim 5 , wherein the disease or disorder is a precancerous lesion, dysplasia, metaplasias or tumor disease. 
     
     
         7 . The method of  claim 6 , wherein the tumor disease is a solid tumor. 
     
     
         8 . The method of  claim 7 , wherein the solid tumor is an epithelial tumor. 
     
     
         9 . The method of  claim 8 , wherein the epithelial tumor is uterine carcinoma; lung carcinoma; gastrointestinal tract carcinoma, kidney cancer; thyroid carcinoma; or adrenal carcinoma. 
     
     
         10 . The method of  claim 5 , wherein the pharmaceutical composition comprises at least one other active ingredient. 
     
     
         11 . The method of  claim 5 , wherein the compound or pharmaceutical composition is administered with a second composition comprising at least one other active ingredient. 
     
     
         12 . The method of  claim 11 , wherein the second composition is suitable for simultaneous, separate or sequential administration.